DK1558649T3 - Peptid til modulering af caspaseaktivering - Google Patents

Peptid til modulering af caspaseaktivering

Info

Publication number
DK1558649T3
DK1558649T3 DK03753618.2T DK03753618T DK1558649T3 DK 1558649 T3 DK1558649 T3 DK 1558649T3 DK 03753618 T DK03753618 T DK 03753618T DK 1558649 T3 DK1558649 T3 DK 1558649T3
Authority
DK
Denmark
Prior art keywords
asp
peptides
structures
fetoprotein
sequences
Prior art date
Application number
DK03753618.2T
Other languages
English (en)
Inventor
Timo Kalevi Korpela
Lidia Nikolaevna Semenkova
Eduard Borisovich Tatulov
Igor Vyacheslavovich Dudich
Dmitry Lvovich Zubov
Elena Ivanovna Dudich
Original Assignee
Elena Ivanovna Dudich
Eduard Borisovich Tatulov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elena Ivanovna Dudich, Eduard Borisovich Tatulov filed Critical Elena Ivanovna Dudich
Application granted granted Critical
Publication of DK1558649T3 publication Critical patent/DK1558649T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03753618.2T 2002-10-09 2003-10-07 Peptid til modulering af caspaseaktivering DK1558649T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20021798A FI118263B (fi) 2002-10-09 2002-10-09 Kaspaasiaktiivisuutta säätelevät peptidit
PCT/FI2003/000735 WO2004033500A1 (en) 2002-10-09 2003-10-07 Peptides modulating caspase activation

Publications (1)

Publication Number Publication Date
DK1558649T3 true DK1558649T3 (da) 2010-10-11

Family

ID=8564726

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03753618.2T DK1558649T3 (da) 2002-10-09 2003-10-07 Peptid til modulering af caspaseaktivering

Country Status (13)

Country Link
US (1) US7446095B2 (da)
EP (1) EP1558649B1 (da)
JP (1) JP4446121B2 (da)
CN (1) CN100551930C (da)
AT (1) ATE470677T1 (da)
AU (1) AU2003271784A1 (da)
DE (1) DE60332950D1 (da)
DK (1) DK1558649T3 (da)
EA (1) EA010058B1 (da)
ES (1) ES2347234T3 (da)
FI (1) FI118263B (da)
PT (1) PT1558649E (da)
WO (1) WO2004033500A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444105A4 (en) * 2009-06-16 2013-08-21 Univ Tokai GRAM NEGATIVE ANTI-BACTERIAL AGENT
CN101812448B (zh) * 2010-01-15 2011-12-07 浙江大学 一种肝癌靶向双重组凋亡蛋白表达序列及应用
CN102060913B (zh) * 2010-11-30 2012-09-05 暨南大学 一种与人血清白蛋白结合的七肽与应用
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
CN108186666B (zh) * 2018-01-29 2020-02-21 西北大学 一种dna纳米带在抗细胞凋亡上的应用及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
CN1150030C (zh) * 1995-01-24 2004-05-19 马蒂尼克斯研究与发展公司 重组人甲胎蛋白及其用途
WO1998010792A1 (en) 1996-09-11 1998-03-19 Prendergast Patrick T Immune direction therapy
EP0979239B1 (en) * 1997-02-13 2006-10-18 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
WO2001015709A1 (en) * 1999-09-02 2001-03-08 Atlantic Biopharmaceuticals, Inc. USE OF rAFP TO INHIBIT OR PREVENT APOPTOSIS
DE60143818D1 (de) * 2001-06-02 2011-02-17 Clf Medical Technology Acceleration Program Inc Alpha-fetoprotein-peptide und ihre verwendung

Also Published As

Publication number Publication date
EP1558649B1 (en) 2010-06-09
US7446095B2 (en) 2008-11-04
JP4446121B2 (ja) 2010-04-07
ES2347234T3 (es) 2010-10-27
WO2004033500A1 (en) 2004-04-22
US20060280732A1 (en) 2006-12-14
AU2003271784A1 (en) 2004-05-04
DE60332950D1 (de) 2010-07-22
FI20021798A (fi) 2004-04-10
CN100551930C (zh) 2009-10-21
ATE470677T1 (de) 2010-06-15
EP1558649A1 (en) 2005-08-03
FI118263B (fi) 2007-09-14
FI20021798A0 (fi) 2002-10-09
PT1558649E (pt) 2010-09-14
EA010058B1 (ru) 2008-06-30
CN1703428A (zh) 2005-11-30
EA200500606A1 (ru) 2006-06-30
JP2006518703A (ja) 2006-08-17

Similar Documents

Publication Publication Date Title
CY1117244T1 (el) Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος
PE20080339A1 (es) Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento
Buckton et al. Improving the cell permeability of polar cyclic peptides by replacing residues with alkylated amino acids, asparagines, and d-amino acids
ES2739676T3 (es) Péptidos biológicamente activos
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
ATE517874T1 (de) Pyrimidinone als modulatoren von caseinkinase ii (ck2)
ATE533514T1 (de) Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern
HRP20050024A2 (en) Pegylated t20 polypeptide
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
DK1558649T3 (da) Peptid til modulering af caspaseaktivering
RU2012129208A (ru) Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
Valldorf et al. An Apoptosis‐Inducing Peptidic Heptad That Efficiently Clusters Death Receptor 5
Martínez et al. Hydrogen bonded squaramide-based foldable module induces both β-and α-turns in hairpin structures of α-peptides in water
SI2797950T1 (en) Fusion protein against cancer
Kukowska-Kaszuba et al. Solid phase synthesis and biological activity of tuftsin conjugates
AR029810A1 (es) Metodos y composiciones para la inhibicion de los acontecimientos asociados con la fusion de membrana, incluyendo la transmision de rsv
Jiang et al. Design and synthesis of redox stable analogues of sunflower trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of matriptase
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
Kuncewicz et al. BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation–design, synthesis and biological evaluation
RU2011110711A (ru) Новые биологически активные пептиды и их новое применение
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
Zhang et al. Kilogram-scale synthesis of osteogenic growth peptide (10–14) using a fragment coupling approach
DOP2002000548A (es) Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epiteliales
ATE439371T1 (de) Synthese von peptid t-1249 mit peptidzwischenproduktfragmenten